HOOK Hookipa Pharma

HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023

HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023

NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2022 financial results before the market opens on Wednesday, March 15, 2023. The Company will host a live conference call and webcast at 8:30 AM ET to discuss its financial results and provide a corporate update.

Conference Call & Webcast:
    
Date:  March 15, 2023
Time:  8:30 AM ET
USA Dial In:  
UK Dial In:  0800-260-6466
Austria Dial In:  
Conference ID:  7669853
Webcast:  



The webcast and the presentation will also be available within the Investors & Media section of HOOKIPA’s website at .

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at .

For further information, please contact:
Media  Investors
Instinctif Partners    Matt Beck
  Executive Director - Investor Relations
+44 (0)20 7457 2020  
   



 



EN
08/03/2023

Underlying

HOOKHookipa Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hookipa Pharma

 PRESS RELEASE
Free
HOOK HOOKIPA PHARMA

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Upd...

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. For imm...

January 10, 2025 1 EN
 PRESS RELEASE
Free
HOOK HOOKIPA PHARMA

HOOKIPA Pharma Inc - FORM 8 (OPD)

HOOKIPA Pharma Inc - FORM 8 (OPD) NEW YORK and VIENNA, Austria, Jan. 08, 2025 (GLOBE NEWSWIRE) -- FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFERRules 8.1 and 8.2 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:HOOKIPA Pharma Inc.(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A(c)   Name of offeror/offeree in relation to whose relevant secu...

January 8, 2025 1 EN
 PRESS RELEASE
Free
HOOK HOOKIPA PHARMA

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclos...

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced a notice to shareholders regarding U.K. disclosure requirements. HOOKIPA directs the attention of its shareholders to certain disclosure requirements applicable to the potential all-share acquisition by HOOKIPA of Po...

January 7, 2025 1 EN
 PRESS RELEASE
Free
HOOK HOOKIPA PHARMA

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Upd...

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. For im...

January 7, 2025 1 EN
 PRESS RELEASE
Free
HOOK HOOKIPA PHARMA

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 6 January 2025 HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment    NEW YORK and VIENNA, Austria, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The following amendment has been made to the ‘Rule 2.9 Information’ disclosed by HOOKIPA in the Rule 2.4 announcement made on 2 January 2025 regarding the potential combi...

January 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch